Warning: This security is no longer trading.
On November 17, 2021, Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.
Trillium Therapeutics Inc. (TRIL): Price and Financial Metrics
TRIL Price/Volume Stats
| Current price | $18.44 | 52-week high | $20.96 |
| Prev. close | $17.97 | 52-week low | $5.80 |
| Day low | $17.83 | Volume | 26,174,700 |
| Day high | $18.49 | Avg. volume | 1,866,404 |
| 50-day MA | $17.69 | Dividend yield | N/A |
| 200-day MA | $11.97 | Market Cap | 1.94B |
TRIL Stock Price Chart Interactive Chart >
Trillium Therapeutics Inc. (TRIL) Company Bio
Trillium Therapeutics develops therapies for the treatment of cancer. The company was founded in 2004 and is based in Toronto, Canada.
TRIL Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 6,044.62% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 1,328.16% |
| 2019 | -39.77% |
Loading social stream, please wait...